HRC 302

Drug Profile

HRC 302

Alternative Names: Autologous gamma-delta T cell infusion therapy; Gamma-delta T cell therapy - Hemosol BioPharma; HML-115

Latest Information Update: 13 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol BioPharma
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 05 Sep 2007 Hemosol is seeking out-licensing and/or partnering opportunities for HRC 302 (http://www.hemosol.com/)
  • 19 Jul 2007 Hemosol Corp. is now a wholly-owned subsidiary of Catalyst Fund Ltd. Partnership II; the pharmaceutical business will be known as Hemosol BioPharma Inc.
  • 06 Nov 2000 Phase-I clinical trials for Chronic myeloid leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top